Compare Ascendis Pharma A/S (ASND) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Kimberly Clark Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Kimberly Clark Corp trades at $112.39 (market cap $37.31B). The key difference: Kimberly Clark Corp is far larger — about 2.1× Ascendis Pharma A/S's market cap, and Kimberly Clark Corp pays a 4.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KMB | |
|---|---|---|
Market Cap | $17.74B | $37.31B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $136.77 |
52-Week Low | $163.32 | $93.05 |
Enterprise Value | $18.11B | $43.86B |
Dividend Yield | — | 4.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kimberly-Clark (KMB) trades at $112.41, up 2.26% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company maintains strong profitability with a 12.8% net income margin and a high ROE of 146.29%, though revenue declined to $16.45B in 2025. Recent news highlights its dividend reliability and upcoming Q2 2026 results announcement on August 4, 2026.
KMB offers a stable dividend yield and defensive appeal, but faces headwinds from revenue pressure and high valuation multiples. Analyst consensus is mixed with a $109 price target below the current price, suggesting cautious optimism. Key risks include consumer sentiment impacts and input cost inflation, requiring monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
